NMS · Biotechnology
Rigel Pharmaceuticals, Inc. (RIGL) Stock
$48.72
+1.52%
NMS: RIGL
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Bioventus (BVS) Soars 12.4%: Is Further Upside Left in the Stock?
Zacks · Jul 7, 2026
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
PR Newswire · Jul 7, 2026
Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer
PR Newswire · Jul 1, 2026
Rigel Pharmaceuticals Closes Licensing Deal for Breast Cancer Drug Veppanu
MT Newswires · Jun 16, 2026
Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)
PR Newswire · Jun 16, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held3.39%
Institutions Held94.11%
Institutions Float Held97.41%
Peer Comparison
About Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc. is led by CEO Raul R. Rodriguez, employs 162 people, headquartered in US, publicly traded since 2000.
Rigel Pharmaceuticals, Inc. (RIGL) stock trades at $48.72 with a market capitalization of $901.42M. The stock is valued at a price-to-earnings (P/E) ratio of 2.67, price-to-book of 2.05, price-to-sales of 3.15. Over the past 52 weeks the stock has ranged between $24.95 and $52.24, and currently trades 6.7% below its 52-week high.
On profitability, Rigel Pharmaceuticals, Inc. generates a return on equity (ROE) of 96.49% — well above the market average, a sign of a high-quality business, return on capital employed of 20.45%, an operating margin of 42.52%, a net profit margin of 116.30%.